Blueprint Medicines expands oncology portfolio by acquiring Lengo Therapeutics for US$465 million

by | Dec 1, 2021 | , , , | 0

USA – Blueprint Medicines, a US-based biotech that specializes in targeted cancer drugs, is...

Read More